PFIZER INC
PFE · Pharmaceutical Preparations · 5.70B shares · +0%/yr ↑ shares · EDGAR filings ↗
Net buyback after stock comp: $1.5B (gross $2.0B, SBC $525M)
Reference price $25.70 · est. market cap ~$146.5B — last insider sale, 2026-06-09 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
C69Diversified pharma with strong cash generation and margins but only-average ROE and declining revenue.
Strengths
- Top-decile cash generation: FCF $9.1B (98.7th pct), net margin 12.4% (84.5th), ROA 3.7% (88.4th)
- Productive oncology pipeline via Seagen (enzalutamide, talazoparib, tisotumab vedotin all positive Phase 3)
Risks
- ROE only 9% (mediocre for the sector) and revenue declining (-1.6%) on COVID rolloff and looming 2026-2030 LOEs
- Weak liquidity (quick ratio 0.87, 14.1st pct) and acquisition-driven leverage
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- FDA recallFDA recall (Class II) — Vial Label: Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL), Rx only, Distribut (2025-08-04)
- FDA approvalFDA approval — HYMPAVZI (2026-06-05)
- Strong balance sheetStrong balance sheet — $10.3B cash & investments
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Revenue declineRevenue -17.7% YoY
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC +1 more (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-05-18 — PHASE3 · Carcinoma, Non-Small-Cell Lung
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
74.3%
Net margin
12.4%
Return on equity
9.0%
Return on assets
3.7%
Revenue growth (QoQ)
-17.7%
Net-income growth
-3.2%
Debt / equity
0.7×
Current ratio
1.2×
Free cash flow
$9.1B
Tangible book value
-$38.5B
Cash & investments
$10.3B
Stock comp / revenue
1.3%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-09 | DAMICO JENNIFER B. | Sell | 2.0K | $25.70 |
| 2026-03-04 | DAMICO JENNIFER B. | Tax withheld | 826 | $26.62 |
| 2026-03-03 | DAMICO JENNIFER B. | Grant | 5.4K | — |
| 2026-03-03 | DAMICO JENNIFER B. | Grant | 16K | — |
| 2026-02-27 | DAMICO JENNIFER B. | Tax withheld | 655 | $27.65 |
| 2026-02-26 | McDermott Michael | Tax withheld | 3.5K | $27.10 |
| 2026-02-25 | LANKLER DOUGLAS M | Tax withheld | 117K | $26.92 |
| 2026-02-25 | DAMICO JENNIFER B. | Option exercise | 18K | $33.82 |
| 2026-02-25 | DAMICO JENNIFER B. | Tax withheld | 361 | $27.09 |
| 2026-02-25 | DAMICO JENNIFER B. | Tax withheld | 17K | $26.92 |
| 2026-02-25 | BOURLA ALBERT | Option exercise | 492K | $33.82 |
| 2026-02-25 | BOURLA ALBERT | Tax withheld | 467K | $26.92 |
| 2026-02-25 | Fonseca Lidia | Option exercise | 57K | $33.82 |
| 2026-02-25 | Fonseca Lidia | Tax withheld | 1.1K | $27.09 |
| 2026-02-25 | Fonseca Lidia | Tax withheld | 54K | $26.92 |
| 2026-02-25 | McDermott Michael | Option exercise | 38K | $33.82 |
| 2026-02-25 | McDermott Michael | Tax withheld | 679 | $27.09 |
| 2026-02-25 | McDermott Michael | Tax withheld | 36K | $26.92 |
| 2026-02-25 | BOSHOFF CHRISTOFFEL | Grant | 13K | — |
| 2026-02-25 | BOSHOFF CHRISTOFFEL | Tax withheld | 6.8K | $27.09 |
| 2026-02-25 | BOURLA ALBERT | Tax withheld | 8.3K | $27.09 |
| 2026-02-25 | SAHNI PAYAL | Option exercise | 57K | $33.82 |
| 2026-02-25 | SAHNI PAYAL | Tax withheld | 1.1K | $27.09 |
| 2026-02-25 | SAHNI PAYAL | Tax withheld | 54K | $26.92 |
| 2026-02-25 | LANKLER DOUGLAS M | Option exercise | 123K | $33.82 |
| 2026-02-25 | LANKLER DOUGLAS M | Tax withheld | 2.2K | $27.09 |
| 2026-02-23 | BOSHOFF CHRISTOFFEL | Tax withheld | 816 | $27.06 |
| 2026-02-23 | DAMICO JENNIFER B. | Tax withheld | 419 | $27.06 |
| 2026-01-30 | BOSHOFF CHRISTOFFEL | Tax withheld | 13K | $26.44 |
| 2025-03-04 | DAMICO JENNIFER B. | Grant | 5.6K | — |
| 2025-03-04 | DAMICO JENNIFER B. | Sell | 2.5K | $25.93 |
| 2025-02-27 | BOURLA ALBERT | Option exercise | 583K | $31.31 |
| 2025-02-27 | DAMICO JENNIFER B. | Tax withheld | 749 | $26.10 |
| 2025-02-27 | DAMICO JENNIFER B. | Option exercise | 22K | $31.31 |
| 2025-02-27 | DAMICO JENNIFER B. | Tax withheld | 553 | $26.10 |
| 2025-02-27 | DAMICO JENNIFER B. | Tax withheld | 21K | $26.06 |
| 2025-02-27 | BOSHOFF CHRISTOFFEL | Grant | 17K | — |
| 2025-02-27 | BOSHOFF CHRISTOFFEL | Tax withheld | 8.9K | $26.10 |
| 2025-02-27 | SUSMAN SALLY | Option exercise | 85K | $31.31 |
| 2025-02-27 | SUSMAN SALLY | Tax withheld | 2.2K | $26.10 |
| 2025-02-27 | SUSMAN SALLY | Tax withheld | 80K | $26.06 |
| 2025-02-27 | SAHNI PAYAL | Option exercise | 19K | $31.31 |
| 2025-02-27 | SAHNI PAYAL | Tax withheld | 468 | $26.10 |
| 2025-02-27 | SAHNI PAYAL | Tax withheld | 18K | $26.06 |
| 2025-02-27 | McDermott Michael | Option exercise | 48K | $31.31 |
| 2025-02-27 | McDermott Michael | Tax withheld | 1.1K | $26.10 |
| 2025-02-27 | McDermott Michael | Tax withheld | 45K | $26.06 |
| 2025-02-27 | LANKLER DOUGLAS M | Option exercise | 157K | $31.31 |
| 2025-02-27 | LANKLER DOUGLAS M | Tax withheld | 3.6K | $26.10 |
| 2025-02-27 | LANKLER DOUGLAS M | Tax withheld | 147K | $26.06 |
| 2025-02-27 | Fonseca Lidia | Option exercise | 73K | $31.31 |
| 2025-02-27 | Fonseca Lidia | Tax withheld | 1.7K | $26.10 |
| 2025-02-27 | Fonseca Lidia | Tax withheld | 68K | $26.06 |
| 2025-02-27 | BOURLA ALBERT | Tax withheld | 18K | $26.10 |
| 2025-02-27 | BOURLA ALBERT | Tax withheld | 546K | $26.06 |
| 2025-02-26 | BOSHOFF CHRISTOFFEL | Grant | 9.7K | — |
| 2025-02-26 | McDermott Michael | Tax withheld | 3.2K | $26.42 |
| 2025-02-26 | BOSHOFF CHRISTOFFEL | Tax withheld | 4.9K | $26.42 |
| 2025-02-24 | DAMICO JENNIFER B. | Tax withheld | 377 | $26.65 |
| 2025-02-24 | BOSHOFF CHRISTOFFEL | Tax withheld | 403 | $26.65 |
| 2025-02-23 | BOSHOFF CHRISTOFFEL | Tax withheld | 662 | $26.30 |
| 2025-02-23 | DAMICO JENNIFER B. | Tax withheld | 390 | $26.30 |
| 2025-02-22 | BOURLA ALBERT | Option exercise | 238K | $30.17 |
| 2025-02-22 | BOURLA ALBERT | Tax withheld | 8.8K | $26.30 |
| 2025-02-22 | BOURLA ALBERT | Tax withheld | 213K | $26.08 |
| 2025-02-22 | LANKLER DOUGLAS M | Tax withheld | 3.3K | $26.30 |
| 2025-02-22 | LANKLER DOUGLAS M | Tax withheld | 77K | $26.08 |
| 2025-02-22 | SAHNI PAYAL | Option exercise | 13K | $30.17 |
| 2025-02-22 | SAHNI PAYAL | Tax withheld | 568 | $26.30 |
| 2025-02-22 | SAHNI PAYAL | Tax withheld | 11K | $26.08 |
| 2025-02-22 | SUSMAN SALLY | Option exercise | 64K | $30.17 |
| 2025-02-22 | SUSMAN SALLY | Tax withheld | 2.8K | $26.30 |
| 2025-02-22 | SUSMAN SALLY | Tax withheld | 57K | $26.08 |
| 2025-02-22 | BOSHOFF CHRISTOFFEL | Option exercise | 8.7K | $30.17 |
| 2025-02-22 | BOSHOFF CHRISTOFFEL | Tax withheld | 340 | $26.30 |
| 2025-02-22 | BOSHOFF CHRISTOFFEL | Tax withheld | 7.8K | $26.08 |
| 2025-02-22 | LANKLER DOUGLAS M | Option exercise | 86K | $30.17 |
| 2025-02-22 | McDermott Michael | Option exercise | 11K | $30.17 |
| 2025-02-22 | McDermott Michael | Tax withheld | 497 | $26.30 |
| 2025-02-22 | McDermott Michael | Tax withheld | 9.9K | $26.08 |
| 2025-02-22 | DAMICO JENNIFER B. | Option exercise | 8.7K | $30.17 |
| 2025-02-22 | DAMICO JENNIFER B. | Tax withheld | 390 | $26.30 |
| 2025-02-22 | DAMICO JENNIFER B. | Tax withheld | 7.8K | $26.08 |
| 2025-02-13 | BLAYLOCK RONALD E | Buy | 19K | $25.65 |
| 2025-01-31 | BOSHOFF CHRISTOFFEL | Tax withheld | 12K | $26.52 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06131840 ↗ | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | PHASE1 | Recruiting | 2029-09-12 |
| NCT06157892 ↗ | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma | PHASE2 | Recruiting | 2029-07-28 |
| NCT05198245 ↗ | Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy Migraine | — | Active Not Recruiting | 2028-04-17 |
| NCT05208762 ↗ | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck | PHASE1 | Recruiting | 2028-01-05 |
| NCT05253651 ↗ | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer Colorectal Neoplasms | PHASE3 | Recruiting | 2027-12-31 |
| NCT07421700 ↗ | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer Urothelial Cancer, Advanced/Metastatic Urothelial Cancer | PHASE1/PHASE2 | Recruiting | 2027-12-06 |
| NCT04227847 ↗ | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Myelodysplastic Syndrome, Acute Myeloid Leukemia | PHASE1 | Recruiting | 2027-07-04 |
| NCT04389632 ↗ | A Study of Sigvotatug Vedotin in Advanced Solid Tumors Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck | PHASE1 | Recruiting | 2027-06-16 |
| NCT05911295 ↗ | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Urothelial Carcinoma | PHASE3 | Active Not Recruiting | 2027-01-29 |
| NCT06125522 ↗ | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) Breast Cancer | PHASE1/PHASE2 | Active Not Recruiting | 2026-12-31 |
| NCT05573555 ↗ | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) Breast Cancer | PHASE1/PHASE2 | Active Not Recruiting | 2026-12-30 |
| NCT05909397 ↗ | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer Breast Cancer | PHASE3 | Active Not Recruiting | 2026-12-30 |
| NCT04879329 ↗ | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 Urothelial Carcinoma | PHASE2 | Recruiting | 2026-12-11 |
| NCT07231991 ↗ | A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function Healthy Participants | PHASE1 | Recruiting | 2026-12-04 |
| NCT05548127 ↗ | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) Breast Cancer | PHASE1/PHASE2 | Active Not Recruiting | 2026-09-01 |
| NCT05571839 ↗ | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors Cutaneous Melanoma, Non-small Cell Lung Cancer | PHASE1 | Active Not Recruiting | 2026-06-06 |
| NCT06012435 ↗ | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung | PHASE3 | Active Not Recruiting | 2026-05-18 |
| NCT06003231 ↗ | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | PHASE2 | Active Not Recruiting | 2026-03-27 |
| NCT03485209 ↗ | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | PHASE2 | Active Not Recruiting | 2026-03-20 |
| NCT04821622 ↗ | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Prostate Cancer | PHASE3 | Active Not Recruiting | 2026-02-18 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (1)
Named in the 10-K; linked when we track them.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-18 | 0000078003-26-000085 ↗ |
| 8-K | 2026-06-18 | 2026-06-18 | 0000078003-26-000087 ↗ |
| 10-Q | 2026-05-05 | 2026-03-29 | 0000078003-26-000054 ↗ |
| 8-K | 2026-05-05 | 2026-05-05 | 0000078003-26-000053 ↗ |
| 8-K | 2026-04-27 | 2026-04-23 | 0000078003-26-000044 ↗ |
| 10-K | 2026-02-26 | 2025-12-31 | 0000078003-26-000026 ↗ |
| 8-K | 2026-02-03 | 2026-02-03 | 0000078003-26-000005 ↗ |
| 8-K | 2025-12-16 | 2025-12-16 | 0000078003-25-000167 ↗ |
| 8-K | 2025-11-21 | 2025-11-18 | 0001193125-25-291406 ↗ |
| 8-K | 2025-11-13 | 2025-11-13 | 0000078003-25-000159 ↗ |
| 8-K | 2025-11-04 | 2025-11-04 | 0000078003-25-000149 ↗ |
| 10-Q | 2025-11-04 | 2025-09-28 | 0000078003-25-000150 ↗ |